Advances in the treatment of male androgenetic alopecia: current options and emerging therapies.
Level 5 - mechanism / opinion, no new human data
Narrative literature review of existing studies without systematic review or meta-analysis methodology
PubMed 40338197 · doi:10.23736/S2784-8671.25.08183-6
What was done
The authors conducted a literature search on PubMed and Google Scholar up to October 31, 2024, to identify English-language reviews, meta-analyses, clinical trials, and case studies on male androgenetic alopecia (AGA) treatments. A total of 149 articles were selected and analyzed.
What was found
The abstract reports no numerical outcome data or effect sizes. Based on the literature synthesis, the authors recommend initiating male AGA management with FDA-approved topical minoxidil and oral finasteride, reserving alternative or emerging therapies for patients who do not tolerate or respond adequately to first-line agents.
Why it matters
This review provides an updated summary of standard and emerging treatment modalities for male pattern hair loss, reinforcing established evidence-based guidelines.
Limits
The abstract provides no quantitative data, effect estimates, or formal systematic review/meta-analytic quality assessments. It is a narrative synthesis of existing literature with potential selection bias, and specifics regarding the efficacy and safety profiles of the reviewed emerging therapies are omitted.
Cited by
- supports Dihydrotestosterone (DHT) is the active metabolite of testosterone that causes male-pattern hair loss.